Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease

NCT06976853 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Crohn Disease (CD)

Interventions

DRUG: Tirzepatide
DRUG: Standard of care treatment

Sponsor

Washington University School of Medicine